ACS Questions October 2012 - aast.org

Pauline K. Park MD, FACS, FCCM

Lena M. Napolitano MD, FACS, FCCM

University of Michigan School of Medicine

Ann Arbor, MI

ACS Questions – October 2012

V. Marco Ranieri MD, et al. JAMA. 2012;():1-8. doi:10.1001/jama.2012.5669

May 21, 2012

AECC

Definition:

Limitations

and

methods to

address

these in the

Berlin

ARDS

Definition

Question 1

All of the following have been demonstrated as

beneficial effects of inhaled nitric oxide in

adult ARDS patients EXCEPT:

A. Significant increase in PaO2

B. Reduced mortality in adult ARDS

C. Decreased pulmonary arterial pressures

D. Improved right ventricular function

Question 1

All of the following have been demonstrated as

beneficial effects of inhaled nitric oside in

adult ARDS patients EXCEPT:

A. Significant increase in PaO2

B. Reduced mortality in adult ARDS

C. Decreased pulmonary arterial pressures

D. Improved right ventricular function

Inhaled Nitric Oxide and ARDS

NO is a selective pulmonary vasodilator that acts on the endothelial

surface of the lung to produce regional vasodilaton in ventilated lung

units, resulting in improved right ventricular function.

NO improves oxygenation in ALI and ARDS, but has no effect on the

duration of ventilatory support or mortality.

Although current cumulative evidence from clinical trials suggests that

NO has no place in the routine therapy of patients with ARDS, short-

term physiologic improvements may be crucial for patient survival in

severe cases for whom refractory hypoxemia or pulmonary

hypertension are major clinical problems.

In these limited situations, NO may have a role as salvage therapy, as a

component of a multimodal approach that includes other strategies

such as high-frequency oscillation and prone positioning.

Inhaled Nitric Oxide and ARDS:

Results of Largest Meta-Analysis

Oxygenation 12 - 24 hrs All-cause Mortality

Included 12 trials and 1237 patients

Adhikari NK et al. BMJ 2007 Apr 14;334(7597):779

RR 1.13, CI 1.04 – 1.23 RR 1.10, CI 0.94 – 1.30

Rescue Strategies in ARDS

Inhaled NO as

Rescue for

Severe ARDS

Question 2

Which of the following factors has the greatest

impact on improving oxygenation in HFOV use

in adult patients with ARDS?

A. Increased mean airway pressure

B. Decreased Hertz

C. Increased inspiratory time

D. Decreased power

HFOV Protocols

Protocol for HFOV in Adults

HFOV Meta-analysis - Oxygenation

PaO2/FiO2 ratio on

days 1 to 3.

HFOV increased

PaO2/FiO2 ratio by

16% to 24%

compared with

conventional

mechanical

ventilation

Sud, BMJ 2010;340:c2327

HFOV Meta-analysis

Sud, BMJ, 2010;340:c2327

HFOV in adults with ARDS is safe and may improve outcome – more study is needed

OSCILLATE RCT CIHR/CCC Trials Group OSCILLATE trial

Target sample size of 1200; 492 enrolled

http://www.oscillatetrial.com/

Randomized Trial

OSCAR: High Frequency OSCillation in ARDS

Target sample size of 802 (6/07 – 2/2012)

Recruitment to date = 762

Funding: NIHR Health Technology Assessment Programme – HTA (UK)

www.oscar-trial.org


HFOV as

Rescue for

Severe ARDS

Question 3

Prone Positioning in adult patients with ARDS is

associated with

A. Improved ventilation

B. Need for neuromuscular blockade

C. Increased complications

D. Reduced mortality in severe hypoxemia patients

Bilateral patchy opacities

ARDS

• “Baby Lung” Sitting on

Top of a Consolidated

Lung

• Posterior dependent

lung consolidation

• Difficult to recruit

CT Imaging prior to Prone Position

Posterior Dependent Atelectasis and Edema

Prone Position effect on Oxygenation

Sud S, et al. CMAJ 2008;178(8):1153-61.

RR 1.23, CI 1.15 – 1.32

Prone Position effect on Mortality

Abroug F, et al. Crit Care 2011;15(1):R6.

In ARDS: RR 0.708, CI 0.503 – 0.997; p=0.048

Prone Position effect on Mortality

Gattinoni L, et al. Minerva Anestesiol 2010;76(6):448-54.

• Individual patient meta-analysis of the 4 major clinical trials

• Absolute mortality of severely hypoxemia ARDS patients is reduced by 10%


Prone Position as

Rescue for Severe

ARDS

Prone Position Techniques

• Vollman Prone Positioner

• Rotoprone Therapy System (KCI, USA)

Prone Positioning

Univ. Michigan Prone

Method

• 4 people

• 2 sheets

• Easy to do

• Easy to teach

• Quick

• Easy access to patient

Question 4

Which of the following is true regarding ECMO in

adult patients with ARDS?

A. VA-ECMO is associated with decreased mortality

compared to VV-ECMO

B. Anticoagulation is required but is not associated with

increased complications

C. Transfer to a specialized center with ECMO

capabilities is associated with decreased mortality

D. ECMO is contraindicated after ≥ 5 days of mechanical

ventilation

ECMO Inclusion Criteria

• Belief that the disease is

reversible

• Severe hypoxemia

• MV with high pressures < 7-

10 days

• Failure of gas exchange

• Failed rescue strategies

Indications Contraindications

Duration of Mechanical

Ventilation

< 5-7 days

7-10 days only if mechanically

ventilated with high pressures

for < 7 days

There is no absolute

contraindications to ECLS, as

each patient is considered

individually with respect to

risks and benefits. There are

conditions, however, that are

known to be associated with a

poor outcome despite ECLS,

and can be considered as

relative contraindications:

Pulmonary Compliance

< 0.5 ml/cm H2O/kg

Mechanical ventilation at high

settings (FiO2 > 0.9, P-plat >

30) for 7 days or more

Oxygenation

PaO2/FiO2 < 100 and no

response to standard

therapies for severe ARDS

Shunt > 30%

Major pharmacologic

immunosuppression (absolute

neutrophil count < 400/mm3)

CNS hemorrhage that is recent or

expanding

Contraindication to systemic

anticoagulation

Exclusion Criteria

• Irreversible pulmonary

disease

• MV > 7-10 days on high

pressures

• Contraindication to

anticoagulation

• N = 1473 from ELSO, mean age 34 years

• 50% all-cause mortality

• ECMO mean duration 144 hours (~6 days)

Brogan TV et al. Intensive Care Med 2009;35(12):2105-14

UK Adult ECMO Study

CESAR. Peek and Firmin 2000-2006

180 ARDS Pts , 30 centers

Consent

Randomize

90 Conventional 90 Optimal+ECMO

47% Survival at 6 months 63% Survival

766 patients screened, 180 randomized, and 68 patients (75%) actually received ECMO. Of patients assigned to consideration for treatment by ECMO, 63% (57/90) survived to 6 months without disability vs 47% (41/87) (relative risk, 0.69; 95% confidence interval [CI], 0·05 - 0·97; P = .03).

(68 ECMO)

Exclusion criteria:

high pressure (30cm

PIP) or high FIO2 (0.8)

for 7d, contraindication

to heparin.

Giles Peek CESAR 2007

ECLS in ARDS

Prospective Randomized Trial, Cesar Trial, 2008 0.0

00.2

50.5

00.7

51.0

0

0 50 100 150 200Analysis time (days)

Conventional ECMO

Kaplan-Meier survival estimates, by allocation

ECMO 63% (57/90) survived to 6 months without disability vs. 47% (41/87) Relative risk (death or severe disability), 0.69; 95% CI 0.05 – 0.97; P = .03; RR death 0.73; 95% CI 0.52-1.03

31% Mortality reduction in Specialized Center

Meta-analysis of 3 ECMO RCTs

• Meta-analysis of the 3 RCTs found

moderate, statistically significant

heterogeneity in their reported risk ratios

for mortality with and without ECMO (chi-

square test p .09, I2 58%).

• This means that differences in patient

populations or methods between the

studies affected the results (not

unexpected considering the trials were

published over a span of 30 yrs) and that

a summary effect size derived from these

published results may not reflect the true

effect of ECMO on patient mortality.

• The summary risk ratio found by the

meta-analysis was 0.93 (95%

confidence interval, 0.71 to 1.22).

• Conclusion:

• Thus, there is insufficient evidence to provide a recommendation for ECMO use among patients with respiratory failure resulting from influenza.

• However, clinicians should consider ECMO within the context of other salvage therapies for acute respiratory failure.

Mitchell MD, et al. Crit Care Med 2010; 38:1398 –1404

Meta-analysis of 3 ECMO RCTs

• Conclusion:

• For clinicians at hospitals that do not have an ECMO program, it

would be advisable:

• to establish institutional guidelines to identify ECMO-eligible

patients in a timely manner and

• to establish a relationship with an ECMO-capable institution to

facilitate safe inter-hospital transport of these potentially

salvageable patients and

• to be familiar with the general guidelines for extracorporeal life

support cases and H1N1 cases in particular provided by the

Extracorporeal Life Support Organization.

• Future studies are needed to define the optimal use of this

potentially life-saving intervention.

Mitchell MD, et al. Crit Care Med 2010; 38:1398 –1404

• ECMO support is a reasonable therapy for patients

who do not respond to conventional care

• Transfer these patients to an ECMO-capable

ARDS referral center with special expertise

• Rescue therapies such as inhaled nitric oxide,

prone positioning, high-frequency oscillatory

ventilation, steroids in ARDS have no better proof

that they are superior to conventional care in

adults with ARDS, but clinicians often use them.

• All ECMO patients should be reported to ELSO

• > 40,000 patients currently in the ELSO registry

Dalton JH and MacLaren G. Crit Care Med 2010; 38(6):1484 –14845

• ICU in Utah

• 30 patients with H1N1-associated ARDS

• Median age 34

• Median P/F ratio 61 (52-100)

• Not treated with ECMO

• Mortality 26.6% (8/30)

• Deaths

• 1 shock/hypoxemia

• 3 severe hypoxic or anoxic brain injury

• 1 strep sepsis

• 1 support withdrawn

Miller RR, et al. CHEST 2010;137:752.

• 2009-2010 H1N1-associated ARDS

• “ECMO-referred patients” 80, transferred to 4 adult ECMO centers in UK

• Matched with “Non-ECMO-referred patients” 1756), Swine Flu Triage Study

• Concurrent longitudinal cohort study

• Critically ill patients with H1N1 ARDS

Noah MA, et al. JAMA 2011;306(15):1659-1668.

80 referred for ECMO; 69 received (86.3%); hospital mortality 27.5%

Noah MA, et al. JAMA 2011;306(15):1659-1668.

EOLIA

ECMO Trial

• ECMO to rescue Lung

Injury in severe ARDS

• Multicenter ECMO trial

in adult severe ARDS

• Alain Combes MD, PI,

• France

• Control cohort with

modern ARDS

ventilator

management, and

rescue strategies

allowed

Judgement criteria

Primary endpoint: all-cause mortality at D60

Secondary outcomes:

– Mortality at D30 and D90, in the ICU and in-hospital

– Number of days, between inclusion and D60, alive without mechanical

ventilation, without hemodynamic support and without organ failure

– Number of patients developing pneumothorax between D1 and D60

– Number of infectious, neurological and hemorrhagic complications

– Duration of mechanical ventilation, and ICU and hospital stays

CARDIOHELP System (Maquet)

• FDA approved 4-26-2011: market in US as cardiac/respiratory assist

device for up to 6 hours, and for ground/air transportation

• HLS Advanced Tubing and Priming Set (2 sets: 7.0 and 5.0)

• Light and compact, touchscreen

• Disposables, integrated sensors (Hb, saO2, sVO2, temperature)

• VV-ECMO or VA-ECMO


ECMO as Rescue for

Severe ARDS

Novalung Active

Heparin-

coated PMP

Hollow fiber

membrane,

Centrifugal

pump

Question 5

What is the optimal timing for tracheostomy in

patients with acute respiratory failure?

A. 1-4 days after intubation

B. 4-6 days after intubation

C. 6-8 days after intubation

D. ≥ 10 days after intubation

Tracheostomy vs. Prolonged Intubation

Crit Care Med 2004 Vol. 32, No. 8:1689

•Adult pts projected to need MV for 14 days

•N = 120

•Early tracheostomy – within 48 hrs

•Late tracheostomy – within 14-16 days

Survival post-intubation

Kaplan-Meier curve. The time to death is displayed. There is a significantly better mortality rate in the early tracheotomy group than the

prolonged translaryngeal group at 30 days (p .005).

Mortality 31.7% vs. 61.7%

Tracheotomy vs. Prolonged Intubation

Outcome Measures

Tracheotomy vs. Prolonged Intubation

•RCT, n = 209

– Early trach, 145 (6-8 days)

– Late trach, 119 (13-15 days)

•12 Italian ICUs, 6/2004-

2008

•Primary endpoint was VAP

– 30 (14%) Early trach

– 44 (21%) Late trach

– P = 0.07 (VAP defined by

CPIS)

Early = 1-4 days after intubation

Late = ≥ 10 days after intubation

TracMan Trial, Largest trial, n=909, UK

•No difference in VAP rates, ventdays, mortality

•Significantly decreased sedation use – early trach

Patient

•A 65 yo female underwent elective pulmonary

lobectomy (RLL) for lung cancer.

•She has a prior 52-pack-year hx of smoking and

PMH of chronic obstructive pulmonary disease

(COPD).

•She requires mechanical ventilation

postoperatively and the RT recognizes that there

is significant auto-PEEP present and notifies you.

Question 6

Which of the following methods would be most

reliable in reducing auto-PEEP?

A. Decrease exogenous positive-end-expiratory

pressure (PEEP)

B. Increase inspiratory time

C. Increase expiratory time

D. Decrease expiratory time

Auto-PEEP

Auto-PEEP & VT

Effect of Lengthening Expiratory time during PCV

flo

wvo

lum

e

Question 7

Regarding Sedation and Delirium in the ICU:

A. Reintubation rates are higher when spontaneous

breathing trials are paired with sedation holidays

B. Dexmedetomidine is associated with higher costs than

lorazepam

C. After adjusting for patient age and severity of illness,

use of lorazepam no longer correlates with the

development of delirium

D. ICU delirium affects long term outcomes following

hospital discharge

Girard, Lancet 2008; 371:126-34

• Paired daily awakening trial and spontaneous breathing trial

• Increased days breathing without assistance and earlier ICU discharge, approx 4 days

• Lower mortality during the year

after enrollment HR 0.68 95% CI 0.50 – 0.92 NTT 7.4

Wake up and Breathe!

Ely JAMA 2004;291:1753-1762

ICU Delirium Affects Mortality at 6 months

Panharipande, Anesthesiology 104 (1) 2006

• Lorazepam use, Severity of illness and Age • Independent risk factors for transitioning to ICU delirium

Choice of sedation is a modifiable risk factor for delirium

Pandharipande, JAMA 2007; 298 (22)

• 106 patients

• Randomized, double blind trial

• Similar costs between

arms

• More days alive without delirium or coma

• More days at targeted

level of sedation

ACS Questions October 2012 - aast.org

Documents

Transcript of ACS Questions October 2012 - aast.org